It has been out in front among orexin agonists being developed for narcolepsy, according to analysts at GlobalData, who have previously suggested it could become a $650 million product by 2027.

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.